Blood Eosinophilia is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA

Blood Eosinophilia is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA

Background: The approvals of immune checkpoint inhibitors for several cancer types and the rapidly growing recognition that T cell-based immunotherapy significantly improves outcomes for cancer patients led to a re-emergence of cancer vaccines, including dendritic cell (DC)-based immunotherapy. Bloo...

Full description

Bibliographic Details
Main Authors: Alvaro Moreira, Michael Erdmann, Ugur Uslu, Verona Vass, Gerold Schuler, Beatrice Schuler-Thurner
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Pharmaceutics
Subjects:
dendritic cell vaccines
biomarkers
eosinophils
Online Access:https://www.mdpi.com/1999-4923/12/3/210

Similar Items

Similar Items